Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 7,176,264 shares, an increase of 3.9% from the October 13th total of 6,905,995 shares. Currently, 6.3% of the shares of the company are sold short. Based on an average trading volume of 880,277 shares, the short-interest ratio is currently 8.2 days.
SYN has been the subject of several recent analyst reports. ValuEngine lowered Synthetic Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. BidaskClub lowered Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Finally, Zacks Investment Research lowered Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.92.
Synthetic Biologics (SYN) opened at $0.67 on Friday. Synthetic Biologics has a twelve month low of $0.41 and a twelve month high of $1.05.
Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10).
TRADEMARK VIOLATION WARNING: This story was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/11/18/short-interest-in-synthetic-biologics-inc-syn-expands-by-3-9.html.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.